Literature DB >> 35043695

Innovative approaches for treatment of osteosarcoma.

Emel Rothzerg1,2, Abigail L Pfaff2,3, Sulev Koks2,3.   

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor, which usually occurs in children and adolescents. It is generally a high-grade malignancy presenting with extreme metastases to the lungs or other bones. The etiology of the disease is multifaceted and still remains obscure. A combination of surgery and chemotherapy has played a major role in the treatment of OS over the past three decades, and consequently, the overall survival rates for the disease have remained unchanged. Therefore, there is an urgent need to employ new comprehensive analyses and technologies to develop significantly more informative classification systems, with the aim of developing more effective and less toxic therapies for OS patients. This review discusses the existing knowledge of OS therapy and potential methods to develop novel therapeutic agents for the disease.

Entities:  

Keywords:  Osteosarcoma; sarcoma; targeted therapy

Mesh:

Year:  2022        PMID: 35043695      PMCID: PMC8899335          DOI: 10.1177/15353702211067718

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  73 in total

Review 1.  Lumasiran: First Approval.

Authors:  Lesley J Scott; Susan J Keam
Journal:  Drugs       Date:  2021-01-06       Impact factor: 9.546

Review 2.  Genetic pharmacology: progresses in siRNA delivery and therapeutic applications.

Authors:  D Scherman; A Rousseau; P Bigey; V Escriou
Journal:  Gene Ther       Date:  2017-01-25       Impact factor: 5.250

3.  Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma.

Authors:  Alessandra Longhi; Stefano Ferrari; Gaetano Bacci; Salvatore Specchia
Journal:  Anticancer Drugs       Date:  2007-07       Impact factor: 2.248

4.  Therapeutic potential of small molecules and engineered proteins.

Authors:  Eugenia V Gurevich; Vsevolod V Gurevich
Journal:  Handb Exp Pharmacol       Date:  2014

Review 5.  The Hippo in the room: Targeting the Hippo signalling pathway for osteosarcoma therapies.

Authors:  Emel Rothzerg; Evan Ingley; Benjamin Mullin; Wei Xue; David Wood; Jiake Xu
Journal:  J Cell Physiol       Date:  2020-07-22       Impact factor: 6.384

Review 6.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

Review 7.  Mechanisms of sarcoma development.

Authors:  Lee J Helman; Paul Meltzer
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

Review 8.  Targeting RNA to treat neuromuscular disease.

Authors:  Francesco Muntoni; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2011-08-01       Impact factor: 84.694

Review 9.  PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy.

Authors:  Si-Min Qi; Jinyun Dong; Zhi-Yuan Xu; Xiang-Dong Cheng; Wei-Dong Zhang; Jiang-Jiang Qin
Journal:  Front Pharmacol       Date:  2021-05-07       Impact factor: 5.810

Review 10.  Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi.

Authors:  Amila Suraweera; Kenneth J O'Byrne; Derek J Richard
Journal:  Front Oncol       Date:  2018-03-29       Impact factor: 6.244

View more
  3 in total

1.  LncRNA SCAMP1 disrupts the balance between miR-26a-5p and ZEB2 to promote osteosarcoma cell viability and invasion.

Authors:  Rong Li; Zhen Chen; Yubo Zhou; Gulikezi Maimaitirexiati; Qi Yan; Yuting Li; Adilijiang Maimaitiyimin; Changhui Zhou; Jingqin Ren; Chengqing Liu; Abasi Mainike; Peng Zhou; Lu Ding
Journal:  Front Oncol       Date:  2022-08-03       Impact factor: 5.738

2.  A 3D Collagen-Based Bioprinted Model to Study Osteosarcoma Invasiveness and Drug Response.

Authors:  Evelin Pellegrini; Giovanna Desando; Mauro Petretta; Antonella Cellamare; Camilla Cristalli; Michela Pasello; Maria Cristina Manara; Brunella Grigolo; Katia Scotlandi
Journal:  Polymers (Basel)       Date:  2022-09-28       Impact factor: 4.967

Review 3.  Proteasome Inhibitors and Their Potential Applicability in Osteosarcoma Treatment.

Authors:  Cassidy M Van Stiphout; Anita K Luu; Alicia M Viloria-Petit
Journal:  Cancers (Basel)       Date:  2022-09-20       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.